Standard BioTools 株価情報 (NASDAQ: LAB)

最新ニュース Standard BioTools (NASDAQ:LAB) 株価情報

Standard BioTools

Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.

Long Ideas

News

Penny Stocks

Insider Trades

Markets

Trading Ideas

CYAN

バタフライ・ネットワークおよびその他2つの5ドル未満の株ダウ平均株価指数は金曜日に50ドル以上上昇して取引を終えた。内部者が株を売買した場合、それは同社の見通しに対する彼らの信頼または懸念を示唆する。ペニー株に興味を持つ投資家やトレーダーは、この要素を総合的な投資や取引の意思決定の一因と考えることができよう。

ダウ平均株価指数は50ドルの上昇を記録　上昇の要因は？

Standard BioTools Inc

Direxion Daily S&P Biotech Bear 3X Shares

LABORATORIOS FARMACEUTICO by LABORATORIOS FARMACEUTICOS ROVI SA

Laboratorios Farmaceuticos Rovi SA

Landos Biopharma Inc COM NEW

LABS Group

Direxion Daily S&P Biotech Bull 3X Shares

METASPHERE LABS INC by METASPHERE LABS INC.

Metasphere Labs Inc

EXEL

Exelixis To Present Preclinical Data For Four Pipeline Molecules At AACR Annual Meeting 2025

Gartner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) has outperformed the market over the past 15 years by 10.47% on an annualized basis producing an average annual return of 21.67%. Currently, Gartner has a market capitalization of $32.40 billion. 
Buying $100 In IT: If an investor had bought $100 of IT stock 15 years ago, it would be worth $1,865.37 today based on a price of $421.76 for IT at the time of writing.
<h3>Gartner's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742937308_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

Earnings

AIRJ

AirJoule Technologies 2024 EPS $4.03 Up From $(0.30) YoY

<h3>Gainers</h3>
<ul>
<li>Springview Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPHL#NASDAQ">SPHL</a>) shares moved upwards by 8.1% to $0.65 during Tuesday's after-market session. The market value of their outstanding shares is at $7.4 million. </li>
<li>Workhorse Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) shares rose 6.46% to $2.46. The market value of their outstanding shares is at $8.0 million. </li>
<li>Rent the Runway (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENT#NASDAQ">RENT</a>) stock rose 5.76% to $4.95. The company's market cap stands at $19.2 million. </li>
<li>SRM Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRM#NASDAQ">SRM</a>) stock rose 5.42% to $0.46. The market value of their outstanding shares is at $7.3 million. </li>
<li>Solo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTC#NYSE">DTC</a>) stock rose 5.14% to $0.19. The company's market cap stands at $11.4 million. </li>
<li>NWTN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) shares moved upwards by 4.99% to $0.43. The company's market cap stands at $124.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Golden Heaven Group Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) stock decreased by 23.6% to $2.91 during Tuesday's after-market session. The market value of their outstanding shares is at $100.4 million. </li>
<li>SAG Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAG#NASDAQ">SAG</a>) stock declined by 8.5% to $0.93. The market value of their outstanding shares is at $9.2 million. </li>
<li>Raytech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAY#NASDAQ">RAY</a>) shares decreased by 6.57% to $1.85. The company's market cap stands at $32.5 million. </li>
<li>U Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCAR#NASDAQ">UCAR</a>) shares decreased by 5.31% to $2.5. The market value of their outstanding shares is at $10.5 million. </li>
<li>Yunji (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YJ#NASDAQ">YJ</a>) shares fell 4.82% to $1.78. The market value of their outstanding shares is at $35.0 million. </li>
<li>Newegg Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) stock declined by 4.3% to $0.26. The company's market cap stands at $97.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

GDHG

NEGG

NWTN

RENT

SPHL

UCAR

WKHS

12 Consumer Discretionary Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) stock increased by 75.8% to $1.19 during Tuesday's after-market session. The market value of their outstanding shares is at $4.6 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock increased by 24.07% to $0.67. The company's market cap stands at $2.9 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock rose 9.46% to $4.51. The market value of their outstanding shares is at $92.5 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock increased by 8.68% to $0.06. The market value of their outstanding shares is at $1.5 million. </li>
<li>Chemomab Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMMB#NASDAQ">CMMB</a>) shares moved upwards by 6.43% to $1.22. The company's market cap stands at $22.9 million. </li>
<li>Bicara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) shares rose 5.9% to $13.8. The market value of their outstanding shares is at $750.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) shares fell 25.0% to $0.15 during Tuesday's after-market session. </li>
<li>Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) stock fell 19.52% to $2.31. The market value of their outstanding shares is at $297.2 million. </li>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares declined by 12.27% to $3.29. The market value of their outstanding shares is at $10.3 million. The company's, Q4 earnings came out 3 days ago. </li>
<li>Galecto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLTO#NASDAQ">GLTO</a>) stock declined by 10.21% to $4.4. The company's market cap stands at $5.7 million. The company's, Q4 earnings came out 4 days ago. </li>
<li>Capstone Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPS#NASDAQ">CAPS</a>) shares fell 8.57% to $2.67. The market value of their outstanding shares is at $3.7 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) shares fell 8.15% to $0.9. The company's market cap stands at $12.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BACK

BCAX

CAPS

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

DBVT

GLTO

HUMA

KAPA

PLRZ

PTPI

TNON

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Samfine Creation Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFHG#NASDAQ">SFHG</a>) shares moved upwards by 23.0% to $1.07 during Tuesday's after-market session. The market value of their outstanding shares is at $23.8 million. </li>
<li>Lucas GC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCL#NASDAQ">LGCL</a>) shares moved upwards by 9.32% to $0.6. The company's market cap stands at $47.5 million. </li>
<li>Galaxy Payroll Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLXG#NASDAQ">GLXG</a>) shares moved upwards by 5.97% to $0.78. The company's market cap stands at $14.0 million. </li>
<li>Hyperscale Data (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#AMEX">GPUS</a>) stock rose 5.08% to $2.52. The market value of their outstanding shares is at $2.7 million. </li>
<li>Vast Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) shares increased by 5.05% to $0.36. The market value of their outstanding shares is at $10.9 million. </li>
<li>Babcock &amp; Wilcox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BW#NYSE">BW</a>) shares increased by 5.03% to $0.9. The market value of their outstanding shares is at $85.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>1847 Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#AMEX">EFSH</a>) shares declined by 6.7% to $0.14 during Tuesday's after-market session. The company's market cap stands at $3.8 million. </li>
<li>Micropolis Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MCRP#AMEX">MCRP</a>) stock decreased by 5.39% to $3.05. The market value of their outstanding shares is at $103.2 million. </li>
<li>ACV Auctions Inc. Class A Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACVA#NYSE">ACVA</a>) shares declined by 4.82% to $15.57. </li>
<li>Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) stock decreased by 4.64% to $1.01. The company's market cap stands at $3.1 million. </li>
<li>Safe &amp; Green Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) shares decreased by 4.3% to $0.49. The market value of their outstanding shares is at $3.0 million. </li>
<li>TPI Composites (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>) shares decreased by 3.64% to $0.95. The market value of their outstanding shares is at $45.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACVA

EFSH

GLXG

GPUS

LGCL

MCRP

SFHG

SGBX

TPIC

VSTE

XPON

12 Industrials Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>CISO Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CISO#NASDAQ">CISO</a>) stock increased by 19.5% to $0.54 during Tuesday's after-market session. The company's market cap stands at $7.7 million. </li>
<li>UTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) shares increased by 11.66% to $0.23. The market value of their outstanding shares is at $5.8 million. </li>
<li>Digital Ally (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) stock moved upwards by 5.55% to $0.04. </li>
<li>Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) stock increased by 4.98% to $41.09. The market value of their outstanding shares is at $4.2 billion. </li>
<li>Cloudastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSAI#NASDAQ">CSAI</a>) stock rose 4.75% to $5.95. The market value of their outstanding shares is at $91.9 million. </li>
<li>T Stamp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDAI#NASDAQ">IDAI</a>) stock increased by 4.3% to $2.18. The market value of their outstanding shares is at $4.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Tungray Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRSG#NASDAQ">TRSG</a>) stock declined by 10.2% to $1.58 during Tuesday's after-market session. The market value of their outstanding shares is at $25.8 million. </li>
<li>X3 Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTKG#NASDAQ">XTKG</a>) shares decreased by 7.9% to $1.05. The market value of their outstanding shares is at $14.4 million. </li>
<li>Baijiayun Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTC#NASDAQ">RTC</a>) stock decreased by 6.87% to $0.3. The market value of their outstanding shares is at $7.6 million. </li>
<li>Sagtec Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGT#NASDAQ">SAGT</a>) stock decreased by 4.99% to $3.24. The market value of their outstanding shares is at $40.6 million. </li>
<li>Inseego (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSG#NASDAQ">INSG</a>) shares decreased by 4.93% to $9.08. The market value of their outstanding shares is at $136.2 million. </li>
<li>Focus Universal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCUV#NASDAQ">FCUV</a>) shares fell 4.5% to $4.46. The market value of their outstanding shares is at $33.0 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BRZE

CISO

CSAI

DGLY

FCUV

IDAI

INSG

SAGT

TRSG

XTKG

12 Information Technology Stocks Moving In Tuesday's After-Market Session

NOAH

Noah Holdings Q4 Adj EPADS $0.26, Net Revenues $89.3M

If you&#8217;re analyzing contrarian opportunities in 2025, this list is worth studying. It highlights names that, despite widespread skepticism, have been <a href="https://www.benzinga.com/analyst-stock-ratings">outperforming more popular picks.</a>
In a year when Wall Street&#8217;s darlings have stumbled, some of the most unloved names in the S&amp;P 500 are quietly delivering gains that put high-conviction buys to shame—and the data may challenge how investors think about analyst ratings.
In a newsletter sent Tuesday, DataTrek Research spotlighted what it called "a truly remarkable list": the 10 S&amp;P 500 companies with the highest share of &#8216;Sell&#8217; ratings from analysts. 
&#8220;History and year-to-date returns suggest it is a good place to look for longs,&#8221; analysts suggested.
<h3 class="wp-block-heading">The Contrarian Play: Most-Hated, Yet Outperforming</h3>
&#8220;Wall Street analysts don&#8217;t put &#8216;Sell&#8217; on many stocks,&#8221; Datatrek wrote.
FactSet data shows that of the 12,320 ratings issued on S&amp;P 500 stocks, 55.7% are Buys, 38.7% are Holds, and only 5.6% are Sells.
&#8220;The percentage of Buy ratings is above its 5-year (month-end) average of 55.0%. The percentage Hold ratings is below its 5-year (month-end) average of 39.1%. The percentage of Sell ratings is also below its 5-year (month-end) average of 5.9%,&#8221; FactSet said.
Here are the 10 S&amp;P 500 stocks with the highest percentage of Sell ratings:
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>Buy</td>
<td>Hold</td>
<td>Sell</td>
</tr>
<tr>
<td>Franklin Resources, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>)</td>
<td>0%</td>
<td>60%</td>
<td>40%</td>
</tr>
<tr>
<td>VeriSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>)</td>
<td>40%</td>
<td>20%</td>
<td>40%</td>
</tr>
<tr>
<td>Expeditors Intl. of Washington, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXPD#NYSE">EXPD</a>)</td>
<td>0%</td>
<td>61%</td>
<td>39%</td>
</tr>
<tr>
<td>T. Rowe Price Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>)</td>
<td>6%</td>
<td>59%</td>
<td>35%</td>
</tr>
<tr>
<td>Paramount Global Class B (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)</td>
<td>13%</td>
<td>52%</td>
<td>35%</td>
</tr>
<tr>
<td>FactSet Research Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>)</td>
<td>17%</td>
<td>50%</td>
<td>33%</td>
</tr>
<tr>
<td>Lennox International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>)</td>
<td>24%</td>
<td>43%</td>
<td>33%</td>
</tr>
<tr>
<td>Garmin Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>)</td>
<td>10%</td>
<td>60%</td>
<td>30%</td>
</tr>
<tr>
<td>Consolidated Edison, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ED#NYSE">ED</a>)</td>
<td>6%</td>
<td>65%</td>
<td>29%</td>
</tr>
<tr>
<td>Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>)</td>
<td>20%</td>
<td>52%</td>
<td>28%</td>
</tr>
</tbody>
</table>
</figure>
As counterintuitive as it may seem, an equal-weighted portfolio of these &#8220;Sell-rated&#8221; stocks would have returned 3.89% year-to-date through March 25, 2025.
Here&#8217;s how the individual &#8220;Sell&#8221; stocks performed:
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Total Return (YTD)</td>
</tr>
<tr>
<td>Consolidated Edison, Inc.</td>
<td>19.35%</td>
</tr>
<tr>
<td>VeriSign, Inc.</td>
<td>18.78%</td>
</tr>
<tr>
<td>Paramount Global</td>
<td>11.45%</td>
</tr>
<tr>
<td>Expeditors International of Washington, Inc.</td>
<td>6.88%</td>
</tr>
<tr>
<td>Garmin Ltd.</td>
<td>6.33%</td>
</tr>
<tr>
<td>Southwest Airlines Co.</td>
<td>3.72%</td>
</tr>
<tr>
<td>Franklin Resources, Inc.</td>
<td>-1.33%</td>
</tr>
<tr>
<td>Lennox International Inc.</td>
<td>-3.62%</td>
</tr>
<tr>
<td>FactSet Research Systems Inc.</td>
<td>-8.25%</td>
</tr>
<tr>
<td>T. Rowe Price Group, Inc.</td>
<td>-14.42%</td>
</tr>
</tbody>
<tfoot>
<tr>
<td>Average</td>
<td>3.89%</td>
</tr>
</tfoot>
</table>
</figure>
That performance handily beats the -2.36% decline of the S&amp;P 500, as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), and it's miles ahead of the -10% drop in the Magnificent Seven cohort, tracked by the Roundhill Magnificent Seven ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#NYSE">MAGS</a>).
<h3 class="wp-block-heading">The "Buy" Darlings Didn't Deliver</h3>
Now, contrast that with the 10 most-loved stocks in the S&amp;P 500 — the ones with the highest percentage of Buy ratings.
This basket includes mega-cap giants like Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), and Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), all ranked in the top tier for analyst sentiment.
But the returns tell a different story. An equal-weighted portfolio of these "Buy-rated" favorites would have lost 4.44% so far in 2025.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Buy</th>
<th>Hold</th>
<th>Sell</th>
<th>YTD Return</th>
</tr>
</thead>
<tbody>
<tr>
<td>UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>97%</td>
<td>0%</td>
<td>3%</td>
<td>+1.97%</td>
</tr>
<tr>
<td>Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>)</td>
<td>96%</td>
<td>0%</td>
<td>4%</td>
<td>-19.34%</td>
</tr>
<tr>
<td>VICI Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VICI#NYSE">VICI</a>)</td>
<td>96%</td>
<td>4%</td>
<td>0%</td>
<td>+9.77%</td>
</tr>
<tr>
<td>Microsoft Corp. </td>
<td>95%</td>
<td>5%</td>
<td>0%</td>
<td>-6.08%</td>
</tr>
<tr>
<td>Amazon.com Inc.</td>
<td>95%</td>
<td>5%</td>
<td>0%</td>
<td>-6.22%</td>
</tr>
<tr>
<td>Nvidia Corp.</td>
<td>93%</td>
<td>7%</td>
<td>0%</td>
<td>-10.14%</td>
</tr>
<tr>
<td>United Airlines Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>)</td>
<td>92%</td>
<td>4%</td>
<td>4%</td>
<td>-18.75%</td>
</tr>
<tr>
<td>Trimble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMB#NASDAQ">TRMB</a>)</td>
<td>92%</td>
<td>8%</td>
<td>0%</td>
<td>-0.27%</td>
</tr>
<tr>
<td>Synopsys Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>)</td>
<td>91%</td>
<td>9%</td>
<td>0%</td>
<td>-5.79%</td>
</tr>
<tr>
<td>Teledyne Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDY#NYSE">TDY</a>)</td>
<td>91%</td>
<td>9%</td>
<td>0%</td>
<td>+10.41%</td>
</tr>
<tr>
<td>Average</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>-4.44%</td>
</tr>
</tbody>
</table>
</figure>
Bottom line, the trend offers a striking insight: being unloved by analysts doesn't necessarily doom a stock to underperformance. 
In fact, in a year marked by pullbacks in big tech and sector rotations, contrarian plays are quietly thriving.
For those willing to swim against the tide, Wall Street's least-favored stocks may hold the key to outperformance this year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/03/44473410/trumps-tariff-rates-could-be-double-what-market-participants-expect-goldman-sachs-warns">Trump&#8217;s Tariff Rates Could Be &#8216;Double What Market Participants Expect,&#8217; Goldman Sachs Warns</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Equities

Large Cap

Sector ETFs

Analyst Ratings

Tech

ETFs

AMZN

EXPD

GRMN

MAGS

MSFT

NVDA

PARA

SNPS

TRMB

TROW

VICI

VRSN

Want To Buy Stocks In 2025? There's One Conflicting Place To Find Winners, Analyst Says

Humacyte Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) shares are tumbling in Tuesday&#8217;s after-hours session after the company <a href="https://www.benzinga.com/pressreleases/25/03/g44481109/humacyte-inc-announces-proposed-public-offering-of-common-stock">announced a proposed public offering</a>.
What Happened: After the market close on Tuesday, Humacyte said it commenced an underwritten public offering of common stock. The biotech platform company plans to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares sold in the offering. Pricing details were not disclosed.
Humacyte intends to use the net proceeds from the offering to fund the commercialization of SYMVESS in the vascular trauma indication, as well as for the development of product candidates in the company&#8217;s pipeline.
Humacyte had $71 million in cash, cash equivalents and restricted cash&nbsp;as of&nbsp;Sept. 30, 2024.
See Also:<a href="https://www.benzinga.com/government/regulations/25/03/44480823/debt-alarm-bells-ring-in-washington-as-moodys-ray-dalio-call-for-urgent-fiscal-discipline"> Debt Alarm Bells Ring In Washington As Moody&#8217;s, Ray Dalio Call For Urgent Fiscal Discipline</a>
<h1 class="wp-block-heading">Is HUMA A Good Stock To Buy?</h1>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action, which you can find on Benzinga's quote pages — like <a href="https://www.benzinga.com/quote/HUMA">Humacyte</a>&#8216;s page, for example — there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the period the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/HUMA">Humacyte</a> will often yield whether or not the company approved a buyback program recently. Buyback programs usually act as a support for share prices, serving as a backstop for demand.
HUMA Price Action: <a href="http://benzinga.com/quote/huma">Humacyte shares</a> were down 21.39% after hours, trading at $2.26 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
This illustration was generated using artificial intelligence via Midjourney.

Biotech

Offerings

After-Hours Center

Humacyte Shares Plunge After Hours: Here's Why

RB Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBA#NYSE">RBA</a>) has outperformed the market over the past 20 years by 3.67% on an annualized basis producing an average annual return of 11.95%. Currently, RB Global has a market capitalization of $18.45 billion. 
Buying $100 In RBA: If an investor had bought $100 of RBA stock 20 years ago, it would be worth $954.30 today based on a price of $99.88 for RBA at the time of writing.
<h3>RB Global's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742936409_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In RB Global 20 Years Ago Would Be Worth This Much Today

Macro Economic Events

Macro Notification

Econ #s

Economics

General

CORRECTION: USA API Weekly Crude Oil Stock 4.600M Barrel Draw Vs 2.500M Barrel Draw Est.; 4.593M Barrel Build Prior

To further financial stability, CISO Global has also secured extensions on convertible notes totaling $7 million.

CISO Global Says It Paid Off Its Highest-interest Loans As Part Of Its Ongoing Efforts To Strengthen Its Balance Sheet

GFL Environmental Reveals Direct Share Buyback Of 17.05M Subordinate Voting Shares From BC Partners And Intention To Buyback Up To 7.056M Subordinate Voting Shares In Secondary Offering

Sesame Workshop, the nonprofit behind Sesame Street, is grappling with financial turmoil as it loses its lucrative contract with Warner Bros Discovery Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) HBO, which had provided $30-35 million annually for a decade, according to a <a href="https://www.nytimes.com/2025/03/23/business/media/sesame-street-layoffs-funding-cuts.html?utm_campaign=mb&amp;utm_medium=newsletter&amp;utm_source=morning_brew">report</a> by The New York Times.
What To Know: The end of this deal comes at a time when the streaming industry is contracting, with major companies <a href="https://www.benzinga.com/general/entertainment/25/02/43520895/disney-cuts-content-budget-by-1-billion-as-it-pushes-for-efficiency-house-of-mouse-says-too-early-to-revise-guidance-despite-earnings-beat">cutting back on spending</a>.
Adding to the crisis, the Trump administration's <a href="https://www.benzinga.com/25/03/44392153/bill-gates-cautions-trump-administration-his-foundation-cannot-bridge-global-health-funding-gaps-amid-usaid-cuts-reports">cuts</a> to the U.S. Agency for International Development eliminated some key grants, while Sesame Street struggles to compete with newer, high-performing children's shows like Bluey and Cocomelon.
Read Also: <a href="https://www.benzinga.com/government/regulations/25/03/44475192/consumer-confidence-falls-to-lowest-since-2022-as-inflation-tariff-worries-grow">Consumer Confidence Falls To Lowest Since 2022 As Inflation, Tariff Worries Grow</a>
Internal documents reviewed by The Times indicate that without cost-cutting measures, the organization would face a $40 million deficit next year. 
To stabilize operations, Sesame Workshop recently laid off nearly 100 employees—about 20% of its staff—and drew $6 million from its investment fund for the first time in over a decade.
Amid the turmoil, Sesame Street is set for a reimagined 56th season with a new format emphasizing comedy, music and animation. CEO Sherrie Westin, who became chief executive last year, remains confident that the organization will adapt and find a sustainable future.
Read Now:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/03/44473410/trumps-tariff-rates-could-be-double-what-market-participants-expect-goldman-sachs-warns" target="_blank" rel="noreferrer noopener">Trump's Tariff Rates Could Be ‘Double What Market Participants Expect,' Goldman Sachs Warns</a></li>
</ul>
Photo: Shutterstock

Entertainment

Education

Sesame Street Faces Financial Struggles As HBO Deal Ends

The United States has agreed to restore Russia's access to the world market for agricultural and fertilizer exports in the latest push for a full ceasefire agreement between <a href="https://www.benzinga.com/markets/25/03/44455074/oil-rises-as-us-and-russia-begin-talks-in-saudi-arabia-for-ukraine-ceasefire-black-sea-deal">Ukraine and Russia.</a>
The news is dragging down several fertilizer stocks and could see Russian oligarchs who faced previous sanctions fighting back for control of their companies.
What Happened: After Russia invaded Ukraine, sanctions were placed on Russian businesses and oligarchs, while the country <a href="https://www.benzinga.com/general/entertainment/22/03/26191880/how-russia-is-trying-to-replace-mcdonalds-and-peppa-pig">shut down American-owned businesses </a>like restaurants owned by McDonald's.
As part of the latest agreement, the U.S. and Russia have agreed to safe navigation and eliminating the use of force for commercial vessels in the Black Sea.
"The United States will help restore Russia's access to the world market for agricultural and fertilizer exports, lower maritime insurance costs, and&nbsp;enhance access to ports and payment systems for such transactions," a White House press briefing <a href="https://www.whitehouse.gov/briefings-statements/2025/03/outcomes-of-the-united-states-and-russia-expert-groups-on-the-black-sea/#:~:text=The%20United%20States%20will%20help,payment%20systems%20for%20such%20transactions.">said</a>.
Agricultural stocks like Intrepid Potash (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPI#NYSE">IPI</a>), The Mosaic Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>) and Nutrien Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) fell on the news Tuesday.
The agreement could see Russian agricultural companies and financial institutions involved in trade lifted from sanctions and rivals once again with other global agricultural companies.
Read Also: <a href="https://www.benzinga.com/news/global/25/03/44333033/trump-boasts-very-good-chance-of-russia-ukraine-ceasefire-but-zelenskyy-says-putin-broke-deals-25-tim">Trump Boasts &#8216;Very Good Chance&#8217; Of Russia-Ukraine Ceasefire, But Zelenskyy Says Putin Broke Deals 25 Times Before</a>
Why It's Important: Russia was one of the largest agricultural explorers before receiving sanctions after invading Ukraine and seeing its shipping routes under pressure to export to other countries.
Several Russian billionaires also received sanctions and, in some cases, stepped down from leadership roles and handed over stakes in their businesses to trusts or other parties.
With the latest news, time will tell if those Russian billionaires, who were mostly accused of being oligarchs and having close ties to Russian President Vladimir Putin, will be able to profit from the agriculture trade once again.
Andrey Melnichenko is the founder of EuroChem and listed as the 62nd richest person in the world by <a href="https://www.bloomberg.com/billionaires/">Bloomberg</a>. Melnichenko previously withdrew from the board of directors of EuroChem and Suek, a large coal company in the country. EuroChem is now controlled by a trust, which includes Melnichenko's wife.
Dmitry Mazepin founded UralChem Group and acquired several fertilizer producers. He was later sanctioned and lost a legal challenge to European Union sanctions in 2023. The EU said Mazepin was involved in a sector that provided revenue to the Russian Government in their ruling.
Mazepin was one of the last Russian businessmen to meet with Putin before Russia invaded Ukraine, according to a report from <a href="https://www.bloomberg.com/news/articles/2025-03-25/us-says-russia-ukraine-agree-ceasefire-in-black-sea">Bloomberg</a> citing the Kremlin website. Mazepin had to give up <a href="https://www.bloomberg.com/news/articles/2023-11-08/russian-fertilizer-tycoon-mazepin-loses-eu-sanctions-appeal?utm_source=chatgpt.com&amp;sref=TBDibEcD">control </a>of UralChem as part of sanctions.
The new agreement, which could push Russia's agriculture exports forward, could be good for the country and help the government raise money to support the war cause or to get the country back on its feet if a full ceasefire is reached.
Russian billionaires will likely fight for control of their companies, which could be an upcoming battle to watch.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/23/08/33849346/is-putin-starving-the-world-political-scientist-unravels-russias-strategy-in-ukraine">Is Putin &#8216;Starving The World&#8217;?: Political Scientist Unravels Russia&#8217;s Strategy In Ukraine</a></li>
</ul>
Photo: Shutterstock

Commodities

Politics

Global

U.S. Restores Russian Access To Fertilizer Exports: Could Sanctioned Oligarchs Benefit From Latest Push In Ceasefire Talks?

BHIL

Benson Hill Gets Court Approval Of First-Day Motions Following Its Filing For Bankruptcy Relief Under Chapter 11

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) has outperformed the market over the past 20 years by 6.62% on an annualized basis producing an average annual return of 14.89%. Currently, Chemed has a market capitalization of $8.91 billion. 
Buying $1000 In CHE: If an investor had bought $1000 of CHE stock 20 years ago, it would be worth $15,933.32 today based on a price of $608.90 for CHE at the time of writing.
<h3>Chemed's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742935513_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Chemed 20 Years Ago Would Be Worth Today

According to the largest provider of private-label credit cards in the U.S., consumers — pressured by years of persistent inflation — are reducing spending as the <a href="https://www.benzinga.com/government/regulations/25/03/44475192/consumer-confidence-falls-to-lowest-since-2022-as-inflation-tariff-worries-grow">economic outlook worsens</a>.
What To Know: Synchrony Financial's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>) chief credit officer Max Axler told Reuters that while most borrowers continue repaying loans, spending has dipped across income levels. 
&#8220;Purchase volumes have gone down across the industry as consumers across all income groups become more thoughtful about spending,&#8221; Axler said.
Read Next:<a href="https://www.benzinga.com/25/03/44475805/homebuilders-kb-home-lennar-cut-prices-as-homebuyer-demand-has-slowed-materially"> Homebuilders KB Home, Lennar Cut Prices As Buyer Demand Has &#8216;Slowed Materially&#8217;</a>
The latest data released by the Consumer Confidence Board on Tuesday showed that pessimism about the economic future is gripping American consumers. The Consumer Confidence Index fell 7.2 points in March to 92.9, its fourth consecutive monthly decline and the lowest reading since late 2022. 
According to recent Federal Reserve data, <a href="https://www.benzinga.com/news/econ-s/25/03/44439342/are-us-consumers-starting-to-crack-pessimism-loan-defaults-bargain-hunting-rise">delinquencies</a> on auto loans, credit cards, and home credit lines have increased, and economists warn that President Donald Trump's tariffs may exacerbate price pressures. 
Consumers may soon face additional financial strain as student loan servicers resume reporting delinquencies to credit bureaus. The process, which began in mid-February 2025, could worsen already stretched household finances.
&#8220;For the first time in five years, federal student loan delinquencies will start to reappear on credit files, and we expect a lot of consumers to be stretched due to this,&#8221; Rikard Bandebo, chief economist at VantageScore, told Reuters. 
&#8220;We expect delinquencies to go up as a result of it at a time when consumer debt is already high,&#8221; Bandebo added.
Concerns about consumer strength have also weighed on financial stocks. Shares of Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) have shed nearly 10% over the past month, and Capital One Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) are down 6% over the same period.
The SPDR Select Financial Sector Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>), which holds 73 large-cap financial stocks, has dipped 1% over the past 30 days on broad consumer spending concerns.&nbsp;
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/global/25/03/44477467/trumps-tariffs-on-buyers-of-venezuelan-oil-could-boost-energy-sector-exxon-mobil-stock">Trump&#8217;s Tariffs On Buyers Of Venezuelan Oil Could Boost Energy Sector, Exxon Mobil Stock&nbsp;</a></li>
</ul>
Image: Shutterstock&nbsp;

Short Sellers

Federal Reserve

Major Credit Card Provider Warns US Consumers Are Spending Less

CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Foghorn&#xAE; Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHTX#NASDAQ">FHTX</a>), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that new preclinical combination data for FHD-909, a potential first-in-class selective SMARCA2 inhibitor will be presented as an oral presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting being held April 25-30, 2025, in Chicago, Illinois. Poster presentations on the Phase 1 trial design for FHD-909 and on preclinical data for the Selective CBP program and the Selective EP300 degrader program will also be presented.
"We are excited to share new preclinical data at this year's AACR conference further strengthening the promise of our differentiated programs," said Adrian Gottschalk, President, and Chief Executive Officer of Foghorn. "Importantly, enrollment and dose escalation are on track in the ongoing Phase 1 trial evaluating FHD-909, a first-in-class oral selective SMARCA2 inhibitor, in SMARCA4 mutated cancers with initial focus in NSCLC. New preclinical data on expansion opportunities for FHD-909 in combination with chemotherapy, pembrolizumab and KRAS inhibitors, in SMARCA4 mutant cancers will be featured in an oral presentation. We look forward to continued progress on our FHD-909 program in collaboration with Lilly."
Mr. Gottschalk added,&nbsp;"Our Selective CBP degrader and Selective EP300 degrader programs have shown highly selective and robust anti-tumor activities, and two poster presentations will highlight preclinical data supporting their advancement towards the clinic. Our pipeline programs continue to show unmatched selectivity for challenging targets, and we are focused on strong execution across our portfolio."

FHTX

Foghorn Therapeutics Will Present New Preclinical Data For Selective SMARCA2 Inhibitor FHD-909 And Selective CBP And EP300 Degrader Programs At 2025 AACR Meeting In Chicago April 24-20, 2025

Press Releases

Standard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024

Standard BioTools Reports Third Quarter 2024 Financial Results

Standard BioTools to Participate in Upcoming Investor Conferences

Management

Standard BioTools Appoints Alex Kim as Chief Financial Officer

Health Care

Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue

Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025

Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Atlantic International Corp. - Common Stock

Atlantic International

Azenta

BioLife Solutions

Codexis

Champions Oncology

Cytek Biosciences

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Fortrea Holdings

Lifecore Biomedical

Mesa Laboratories

Maravai LifeSciences Holdings, Inc. - Class A common stock

Maravai LifeSciences

MaxCyte

Niagen Bioscience

OmniAb

Pacific Biosciences of California, Inc. - Common Stock

Pacific Biosciences

Personalis

Quantum-Si Incorporated - Class A Common Stock

Quantum-Si

Quanterix

Sotera Health

Stevanato Group

Alpha Teknova

10x Genomics

TD Cowen

Jefferies

バタフライ・ネットワークおよびその他2つの5ドル未満の株
ダウ平均株価指数は金曜日に50ドル以上上昇して取引を終えた。内部者が株を売買した場合、それは同社の見通しに対する彼らの信頼または懸念を示唆する。ペニー株に興味を持つ投資家やトレーダーは、この要素を総合的な投資や取引の意思決定の一因と考えることができよう。
以下に5ドル未満の注目すべきペニー株の最近のインサイダー取引について見てみよう。詳細は<a href="https://www.benzinga.com/sec/insider-trades/">Benzingaのインサイダー取引</a>を参照。
<h3 class="wp-block-heading">Standard BioTools</h3>
<ul>
<li>取引: Standard BioTools Inc(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAB#NASDAQ">LAB</a>)のCasdin Private Growth Equity Fund、L.P.氏が1.61ドルの平均価格で1,069,562株を<a href="https://www.benzinga.com/sec/insider-trades/">合計1,72百万ドルで購入した</a>。</li>
<li>出来事: 7月31日、Standard BioToolsは決算を発表、予想を下回る結果を報告し、2024年度の売上高見通しも引き下げた。</li>
<li>Standard BioToolsの事業:Standard BioToolsは、バイオメディカル研究者が医薬品をより早く開発するためを支援する技術を開発、製造、販売している。</li>
</ul>
<h3 class="wp-block-heading">Cyanotech</h3>
<ul>
<li>取引: Cyanotech Corporation（OTC：<a class="ticker" href="https://www.benzinga.com/stock/CYAN#OTC">CYAN</a>）のMichael A / Davis氏は、0.73ドルの平均価格で1万株を<a href="https://www.benzinga.com/sec/insider-trades/">合計7,250ドルで購入した</a>。</li>
<li>出来事:8月7日、Cyanotechは2024年6月30日に終了した2025会計年度第1四半期の決算を発表した。</li>
<li>Cyanotechの事業: Cyanotech Corpは、栄養補助食品市場向けのミドロモの自然製品を生産している。</li>
</ul>
<h3 class="wp-block-heading">PHX Minerals</h3>
<ul>
<li>取引: PHX Minerals Inc。(NYSE：<a class="ticker" href="https://www.benzinga.com/stock/PHX#NYSE">PHX</a>) SVP – CFOのRaphael D&#8217;Amico氏は3.30ドルの平均価格で1万株を<a href="https://www.benzinga.com/sec/insider-trades/">合計9,898ドルで購入した</a>。</li>
<li>出来事: 8月12日、PHX Mineralsは第3四半期の決算で予想を上回る結果を報告した。</li>
<li>PHX Mineralsの事業: PHX Minerals Incは、掘削から永久ミネラルおよび天然ガスへの所有権への事業の核心を移行させることを目指している石油・天然ガス鉱物会社。</li>
</ul>
次に読むべきは
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40306547/dow-settles-higher-but-records-weekly-loss-greed-index-remains-in-extreme-fear-zone">ダウは高く推移も週間損失を記録、『極度の恐怖』ゾーンに留まるGreed Index</a></li>
</ul>

Comments

Standard BioTools

ニュース

最新ニュース Standard BioTools (NASDAQ:LAB) 株価情報

月曜日, 8 12, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル